Danaher用$180/share 购买Masimo $180/share 在9.9B交易中, 2026年结束。 Danaher to buy Masimo for $180/share in $9.9B deal, closing in 2026.

Danaher公司同意以每个现金份额180美元购买Masimo,估计交易额为99亿美元,预计将在2026年下半年完成。 Danaher Corp has agreed to acquire Masimo for $180 per share in cash, valuing the deal at $9.9 billion, with completion expected in the second half of 2026. 在监管和股东批准之前,这项采购将把Masimo作为一个独立单位纳入Danaher的诊断部分,利用Masimo的脉冲食氧测量技术、AI驱动的监测以及病人护理方面的领导力。 The acquisition, pending regulatory and shareholder approvals, will integrate Masimo as a standalone unit within Danaher’s diagnostics segment, leveraging Masimo’s pulse oximetry technology, AI-enabled monitoring, and leadership in patient care. 这笔交易预计将对Danaher的收入有利,在关闭后的第一个整年中,每股0.15美元至0.20美元,到2027年,EBITDA的收益将超过5.30亿美元。 The deal is projected to be accretive to Danaher’s earnings by $0.15 to $0.20 per share in the first full year post-closing and generate over $530 million in EBITDA by 2027. Danaher将用现金和债务为购买提供资金,目的是推动远程监测和医院在家市场的增长。 Danaher will fund the purchase with cash and debt, aiming to drive growth in remote monitoring and hospital-at-home markets. 马西莫的股票在新闻上上涨了30%以上,反映出市场信心强劲。 Masimo’s stock rose over 30% on the news, reflecting strong market confidence.